Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
Jin Jie(First Affiliated Hospital Zhejiang University), Hong Ma(Fujian Medical University), Siguo Hao(XinHua Hospital), Zonghai Li(Guizhou Normal University), Songfu Jiang(Wenzhou Medical University), Liyuan Ma(State Key Laboratory of Pollution Control and Resource Reuse), Lihui Dai(Wenzhou Medical University), Mingxia He(Wenzhou Medical University), Rong Tao(Shanghai Jiao Tong University), Xin Huang(Capital Medical University), Wei Wang(Central South University), Wenhao Zhang(Northeast Forestry University), Shasha Wang(Chinese PLA General Hospital), Kang Yu(Wenzhou Medical University), Jun Xiao(Regend Therapeutics (China)), Linjun Chen(XinHua Hospital), Min Yang(First Affiliated Hospital Zhejiang University), Daijing Yuan(Regend Therapeutics (China)), Haitao Meng(First Affiliated Hospital Zhejiang University), Chongyun Xing(Zhejiang Chinese Medical University)
Cited by 40
Related Papers
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|238